« Return to News | CROs/Service Providers

Spaulding, Frontage partner in clinical development

Tuesday, September 13, 2011 01:37 PM

Spaulding Clinical Research, the US-based provider of clinical pharmacology and cardiac core-laboratory services is extending its reach further east through an alliance with Frontage Laboratories, according to PharmaTimes.

Under the strategic partnership agreement, Spaulding will conduct all intense electrocardiographic (ECG) studies on behalf of Frontage at its US clinical pharmacology unit in West Bend, Wisconsin as well as providing ECG Core Lab services for its partner.

Frontage, a full-service clinical research organization with facilities in the US and China, will in return offer bioanalytical method development and sample processing, formulation development and clinical trial product supplies on Spaulding’s behalf while serving as one of the clinical sites for Spaulding Clinical clients in China.

Randy Spaulding, chief executive officer and founder of Spaulding Clinical, said the collaboration was “another step forward in meeting our strategic objectives of providing the highest quality global clinical development facilities to our clients interested in accelerating drug development. Together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.